通过向口服和鼻内蛋白体-福氏志贺菌2a脂多糖疫苗中添加霍乱毒素B亚单位来增强抗志贺菌脂多糖（LPS）反应。
Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
作者信息
Orr N, Arnon R, Rubin G, Cohen D, Bercovier H, Lowell G H
机构信息
Medical Corps, Israel Defence Force, Military Post 02149, Rehovot, Israel.
出版信息
Infect Immun. 1994 Nov;62(11):5198-200. doi: 10.1128/iai.62.11.5198-5200.1994.
Abstract
Addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a lipopolysaccharide vaccines improved their immunogenicities. Enhancement of anti-O-Shigella immunoglobulin A levels was most evident in lung lavages following oral immunization and in lung and intestinal fluids when suboptimal doses were used with either immunization route.
摘要
将霍乱毒素B亚基添加到口服和鼻内蛋白酶体-福氏志贺菌2a脂多糖疫苗中可提高其免疫原性。在口服免疫后的肺灌洗中以及在使用次优剂量通过任一免疫途径免疫时，肺和肠道液中的抗O-志贺菌免疫球蛋白A水平的增强最为明显。
相似文献
1
Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.通过向口服和鼻内蛋白体-福氏志贺菌2a脂多糖疫苗中添加霍乱毒素B亚单位来增强抗志贺菌脂多糖（LPS）反应。
Infect Immun. 1994 Nov;62(11):5198-200. doi: 10.1128/iai.62.11.5198-5200.1994.
2
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.口服或鼻内接种弗氏志贺菌2a和宋内志贺菌蛋白酶体-脂多糖疫苗在动物模型中的免疫原性和效力
Infect Immun. 1993 Jun;61(6):2390-5. doi: 10.1128/iai.61.6.2390-2395.1993.
3
Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.霍乱毒素和不耐热肠毒素的天然及突变形式可有效增强减毒活疫苗和热灭活志贺氏菌疫苗的保护效力。
Infect Immun. 1999 Nov;67(11):5841-7. doi: 10.1128/IAI.67.11.5841-5847.1999.
4
DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin.DeltaguaBA减毒福氏志贺菌2a菌株CVD 1204作为一种志贺菌疫苗以及破伤风毒素C片段的活黏膜递送系统。
Vaccine. 2000 Apr 28;18(21):2193-202. doi: 10.1016/s0264-410x(00)00025-6.
5
Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.接种志贺氏菌结合疫苗后，针对宋内志贺氏菌和福氏志贺氏菌2a多糖的IgG类和亚类以及IgA血清反应的定量分析。
Vaccine. 1999 Aug 6;17(23-24):3109-15. doi: 10.1016/s0264-410x(99)00136-x.
6
Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.在接种减毒活福氏志贺菌2a候选疫苗的志愿者中引发的针对脂多糖（LPS）和侵袭质粒抗原（Ipa）B的抗原特异性B记忆细胞反应。
Vaccine. 2009 Jan 22;27(4):565-72. doi: 10.1016/j.vaccine.2008.10.081. Epub 2008 Nov 18.
7
Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.健康成人鼻内接种蛋白酶体-福氏志贺菌2a脂多糖疫苗的安全性和免疫原性。
Infect Immun. 2001 Jul;69(7):4545-53. doi: 10.1128/IAI.69.7.4545-4553.2001.
8
Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.在志贺氏菌感染的小鼠模型中，经鼻内或胃内接种蛋白酶体-志贺氏菌脂多糖疫苗可预防致死性肺炎。
Infect Immun. 1995 Jun;63(6):2382-6. doi: 10.1128/iai.63.6.2382-2386.1995.
9
[The antigenic and immunogenic properties of the bivalent strain Shigella flexneri-Shigella sonnei 1 No. 200].[二价福氏志贺菌-宋内志贺菌1号菌株200的抗原性和免疫原性特性]
Zh Mikrobiol Epidemiol Immunobiol. 1995 Nov-Dec(6):47-8.
10
Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.一种三价福尔马林灭活志贺氏菌全细胞疫苗的研发及临床前评估
Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.
引用本文的文献
1
Development of the 2a, 3a, 6, and artificial Invaplex (Invaplex) vaccines.2a、3a、6 型人工 Invaplex（Invaplex）疫苗的研制。
mSphere. 2023 Aug 24;8(4):e0007323. doi: 10.1128/msphere.00073-23. Epub 2023 Jun 30.
2
From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology.从抗原递呈系统到佐剂活性：纳米颗粒在疫苗学中的广泛应用。
Vaccines (Basel). 2015 Nov 5;3(4):930-9. doi: 10.3390/vaccines3040930.
3
Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.霍乱弧菌 O1 来源的类脂体经鼻腔给药与伤寒沙门氏菌 Vi 多糖联合应用的免疫佐剂效应。
BMC Immunol. 2013;14 Suppl 1(Suppl 1):S10. doi: 10.1186/1471-2172-14-S1-S10. Epub 2013 Feb 25.
4
Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.鼻内和肌肉注射蛋白酶体-葡萄球菌肠毒素B（SEB）类毒素疫苗：对小鼠致死性SEB中毒的免疫原性和疗效
Infect Immun. 1996 May;64(5):1706-13. doi: 10.1128/iai.64.5.1706-1713.1996.
5
Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.在志贺氏菌感染的小鼠模型中，经鼻内或胃内接种蛋白酶体-志贺氏菌脂多糖疫苗可预防致死性肺炎。
Infect Immun. 1995 Jun;63(6):2382-6. doi: 10.1128/iai.63.6.2382-2386.1995.
本文引用的文献
1
Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers.口服全细胞/重组B亚单位霍乱疫苗在北美志愿者中的安全性和免疫原性。
J Infect Dis. 1993 Jun;167(6):1446-9. doi: 10.1093/infdis/167.6.1446.
2
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.口服或鼻内接种弗氏志贺菌2a和宋内志贺菌蛋白酶体-脂多糖疫苗在动物模型中的免疫原性和效力
Infect Immun. 1993 Jun;61(6):2390-5. doi: 10.1128/iai.61.6.2390-2395.1993.
3
Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.通过鼻内应用链球菌表面蛋白抗原与霍乱毒素B亚单位诱导黏膜免疫。
Infect Immun. 1993 Jan;61(1):314-22. doi: 10.1128/iai.61.1.314-322.1993.
4
Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer's patch lymphocyte traffic to the lung: possible implications for infectious disease prophylaxis and therapy.口服一种细菌免疫调节剂可增强小鼠肠道固有层和派尔集合淋巴结淋巴细胞向肺部的迁移：对传染病预防和治疗可能具有的意义。
Int Immunol. 1993 Jan;5(1):29-36. doi: 10.1093/intimm/5.1.29.
5
Immune response related to the molecular structure of a peptide from the cholera toxin B subunit.与霍乱毒素B亚基的一种肽的分子结构相关的免疫反应。
Vaccine. 1993 Sep;11(12):1233-9. doi: 10.1016/0264-410x(93)90048-3.
6
Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.以色列军事人群中针对脂多糖的血清抗体及对志贺氏菌病的天然免疫力
J Infect Dis. 1988 May;157(5):1068-71. doi: 10.1093/infdis/157.5.1068.
7
Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.霍乱毒素对口服抗原的肠道黏膜免疫反应具有强大的佐剂特性。
Immunology. 1986 Oct;59(2):301-8.
8
Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.用流感疫苗经鼻内接种霍乱毒素B亚单位增强保护性抗体反应。
Vaccine. 1989 Jun;7(3):257-62. doi: 10.1016/0264-410x(89)90240-5.
9
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.伤寒沙门氏菌-宋内志贺氏菌二价疫苗预防志贺氏菌病
J Infect Dis. 1987 Jun;155(6):1260-5. doi: 10.1093/infdis/155.6.1260.
10
Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.流感血凝素（HA）疫苗联合霍乱毒素B亚单位鼻内接种与口服或胃肠外接种的比较。
Vaccine. 1990 Jun;8(3):243-8. doi: 10.1016/0264-410x(90)90053-o.
Zotero 插件